Drug intelligence / Profile preview

cephalomannine

Development stage
Preclinical
Modality
Small Molecules
Administration
Intraperitoneal, Intranasal, Oral
01

Overview

Cephalomannine is a naturally occurring **taxane diterpenoid** structurally related to paclitaxel, isolated from various Taxus (yew) species including Taxus yunnanensis and Taxus wallichiana[1][2][4][8][13][18]. It exhibits antitumor and antiproliferative activity by binding to and stabilizing microtubules, which inhibits their depolymerization[4][16]. This leads to arrested mitosis at the G2/M phase and renders it cytotoxic to rapidly dividing cells, particularly cancer cells[4][16]. Cephalomannine induces cell death and has shown potent inhibition of cell proliferation in vitro, with demonstrated activity against cancers including **glioblastoma** and leukemia, in part by promoting autophagy[3][7]. While closely related to paclitaxel, cephalomannine differs at the amide side chain and is considered a natural congener; it has historically been used in research with potential as a chemotherapeutic agent, but is not approved for clinical use in humans[3][10].

Other names
cephalomannineTAXOL BNSC 318735NSC318735NSC-318735Paclitaxel Impurity BPaclitaxel harringine
02

Targets

TUBB (Tubulin (alpha and beta subunits))APEX1 (DNA-apurinic apyrimidinic site lyase)

Beyond the preview

Go deeper on cephalomannine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cephalomannine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call